114 related articles for article (PubMed ID: 7053826)
1. The in vitro effect of a calf thymus extract (thymostimulin) on the immunologic parameters of patients with untreated Hodgkin's disease.
Martelli MF; Velardi A; Rambotti P; Cernetti C; Bracaglia AM; Ballatori E; Davis S
Cancer; 1982 Jan; 49(2):245-50. PubMed ID: 7053826
[TBL] [Abstract][Full Text] [Related]
2. The in vivo effect of a thymic factor (thymostimulin) on immunologic parameters of patients with untreated Hodgkin's disease.
Martelli MF; Velardi A; Rambotti P; Cernetti C; Bertotto A; Spinozzi F; Bracaglia AM; Falini B; Davis S
Cancer; 1982 Aug; 50(3):490-7. PubMed ID: 7046903
[TBL] [Abstract][Full Text] [Related]
3. The in vivo effect of thymic factor (thymostimulin) administration on circulating immune complexes and serum lysozyme levels in untreated Hodgkin's disease patients.
Velardi A; Spinozzi F; Rambotti P; Tabilio A; Losito A; Zampi I; Cernetti C; Martelli MF; Grignani F; Davis S
J Clin Oncol; 1983 Feb; 1(2):117-25. PubMed ID: 6668495
[TBL] [Abstract][Full Text] [Related]
4. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
[TBL] [Abstract][Full Text] [Related]
5. The in vitro effect of a calf thymus extract (thymostimulin) on T cell phenotypes in cord blood lymphocytes.
Velardi A; Gerli R; Rambotti P; Spinozzi F; Cernetti C; Angelini A; Martelli MF
Am J Reprod Immunol (1980); 1982 Oct; 2(5):250-3. PubMed ID: 6217758
[TBL] [Abstract][Full Text] [Related]
6. PHA dose dependent defect in lymphocyte stimulation and E-rosette-forming cells in untreated Hodgkin's disease.
Land JM; Litwin J; Bigel P; Oberling F; Mayer S
Acta Haematol Pol; 1977; 8(2):131-4. PubMed ID: 329629
[TBL] [Abstract][Full Text] [Related]
7. The in vivo effect of thymic factor (thymostimulin) administration in Hodgkin's disease patients. Correlation of skin reactivity and leukocyte migration-inhibition factor in the sera of anergic subjects.
Velardi A; Rambotti P; Cernetti C; Spinozzi F; Bertotto A; Martelli MF
Thymus; 1983 Sep; 5(5-6):429-32. PubMed ID: 6362105
[TBL] [Abstract][Full Text] [Related]
8. The in vitro effect of a calf thymus extract on the peripheral blood lymphocytes of patients with warts.
Bernengo MG; de Matteis A; Meregalli M; Capella G; Zina G
Br J Dermatol; 1980 Jan; 102(1):11-6. PubMed ID: 6966500
[TBL] [Abstract][Full Text] [Related]
9. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
Lang JM; Bigel P; Oberling F; Mayer S
Pathol Biol (Paris); 1978; 26(3-4):159-62. PubMed ID: 355984
[TBL] [Abstract][Full Text] [Related]
10. [Hodgkin's disease. T lymphocyte defect in patients in complete remission (author's transl)].
Lang JM; Bigel P; Oberling F; Mayer S
Sem Hop; 1978 Nov 8-15; 54(37-40):1155-8. PubMed ID: 217096
[TBL] [Abstract][Full Text] [Related]
11. Splenic T and B lymphocytes and their mitogenic response in untreated Hodgkin's disease.
Han T; Minowada J; Subramanian V; Barcos M; Kim U
Cancer; 1980 Feb; 45(4):767-74. PubMed ID: 6965606
[TBL] [Abstract][Full Text] [Related]
12. Normal active rosette-forming-cells in untreated patients with Hodgkin's disease.
Lang JM; Bigel P; Oberling F; Mayer S
Biomedicine; 1977 Dec; 27(9-10):322-4. PubMed ID: 606306
[TBL] [Abstract][Full Text] [Related]
13. E-rosette inhibiting substance in Hodgkin's disease spleen extracts.
Bieber MM; Fuks Z; Kaplan HS
Clin Exp Immunol; 1977 Sep; 29(3):369-75. PubMed ID: 201408
[TBL] [Abstract][Full Text] [Related]
14. The in vitro effect of a calf thymus extract on the peripheral blood lymphocytes of sixty-six melanoma patients.
Bernengo MG; Capella G; de Matteis A; Tovo PA; Zina G
Clin Exp Immunol; 1979 May; 36(2):279-84. PubMed ID: 314368
[TBL] [Abstract][Full Text] [Related]
15. [T and B lymphocytes in chronic lymphocytic leukemia and Hodgkin's disease. Electron microscopic and immunologic studies].
Cohnen G
Veroff Pathol; 1975; (0):1-99. PubMed ID: 49138
[TBL] [Abstract][Full Text] [Related]
16. Role of suppressor cells in depression of T lymphocyte proliferative response in untreated and treated Hodgkin's disease.
Han T
Cancer; 1980 Apr; 45(8):2102-8. PubMed ID: 6445226
[TBL] [Abstract][Full Text] [Related]
17. Reversal of cell surface abnormalities of T lymphocytes in hodgkin's disease after in vitro incubation in fetal sera.
Fuks Z; Strober S; King DP; Kaplan HS
J Immunol; 1976 Oct; 117(4):1331-5. PubMed ID: 1086325
[TBL] [Abstract][Full Text] [Related]
18. In vitro stimulation of T-cell rosette formation by antiserum to thymus factor in Hodgkin's disease.
Zółtowska A; Arendt M; Gan J
Arch Immunol Ther Exp (Warsz); 1984; 32(1):51-7. PubMed ID: 6332594
[TBL] [Abstract][Full Text] [Related]
19. The influence of splenectomy on cellular immunologic parameters in Hodgkin's disease.
Wagener DJ; Geestman E; Borgonjen A; Haanen C
Cancer; 1976 May; 37(5):2212-9. PubMed ID: 130968
[TBL] [Abstract][Full Text] [Related]
20. Five-year survival in Hodgkin's disease. The prospective value of immune status at diagnosis.
van Rijswijk RE; de Meijer A; Sybesma JP; Kater L
Cancer; 1986 Apr; 57(8):1489-96. PubMed ID: 2936444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
